With the rapid spread of SARS-CoV-2 variants, including those that are resistant to
antibodies authorized for emergency use, it is apparent that new antibodies may be needed …

Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …

Background: Coronavirus infection of 2019 (COVID-19) is associated with significant
morbidity and mortality. Vaccines supplement public health and social measures in …

Applying monoclonal antibodies against Covid-19 is a promising treatment option for
avoiding severe outcomes. However, real life data, especially in regional hospitals are still …

Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development
of novel preventive vaccines and effective therapeutics. Passive antibody therapies using …

The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2,
was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to …